This afternoon we watched BeiGene drop -4.4% to a price of $205.44 per share. The Large-Cap Pharmaceutical company is now trading -26.65% below its average target price of $280.06. Analysts have set target prices ranging from $207.0 to $376.0 per share for BeiGene, and have given the stock an average rating of buy.
The stock has a very low short interest at 1.9%, and a short ratio of 3.42. The company's insiders own 19.47% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that only a small number of institutional investors are invested in the stock, with 49.2% of BeiGene's shares being owned by this investor type.
Institutions Invested in BeiGene
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-09-30 | Baker Bros. Advisors, LP | 11% | 10,568,897 | $2,171,274,225 |
| 2024-09-30 | Capital International Investors | 7% | 6,430,884 | $1,321,160,824 |
| 2024-09-30 | HHLR Advisors, LTD | 5% | 5,176,906 | $1,063,543,581 |
| 2024-09-30 | Primecap Management Company | 5% | 4,974,289 | $1,021,917,944 |
| 2024-09-30 | Baillie Gifford and Company | 4% | 3,705,756 | $761,310,521 |
| 2024-09-30 | Price (T.Rowe) Associates Inc | 3% | 2,700,088 | $554,706,085 |
| 2024-09-30 | Temasek Holdings (Private) Limited | 2% | 2,388,576 | $490,709,059 |
| 2024-09-30 | FMR, LLC | 2% | 1,660,011 | $341,032,663 |
| 2024-09-30 | Blackrock Inc. | 1% | 892,349 | $183,324,180 |
| 2024-09-30 | Point72 Asset Management, L.P. | 1% | 667,166 | $137,062,584 |
Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on BeiGene.
